Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Clostridial Collagenase Ointment Clear all
Completed No phase listed Observational

Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

NCT05249257
View directory record Official record
Conditions
Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

NCT00528606
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 6, 2026, 1:03 PM EDT
Not yet recruiting Not applicable Interventional

PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers

NCT07779239
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs)
Interventions
Bonvadis® (NWBOT), Clostridial Collagenase Ointment
Device
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
North Port, Florida • Palm Coast, Florida • South Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Recruiting Not applicable Interventional

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease

NCT06065436
View directory record Official record
Conditions
Peyronie Disease, Erectile Dysfunction
Interventions
Collagenase Clostridium Histolyticum, Storz Duolith LiSWT
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Histopathology Following CCH Injection

NCT04236635
View directory record Official record
Conditions
Characteristics of Subcutaneous Tissue
Interventions
Collagenase Clostridium Histolyticum Single Injection Technique, Collagenase Clostridium Histolyticum Multiple Injection Technique
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Montclair, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT01518907
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
16
States / cities
Beverly Hills, California • Murrieta, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

NCT02889848
View directory record Official record
Conditions
Fibroids, Uterine, Leiomyoma
Interventions
Saline, EN3835
Other · Drug
Lead sponsor
Advance Biofactures Corporation
Industry
Eligibility
35 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
AA4500 0.29 mg/1 mL, AA4500 0.58 mg/2 mL, AA4500 0.58 mg/1 mL, AA4500 0.58 mg/0.5 mL, Shoulder exercises
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 6, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT04209530
View directory record Official record
Conditions
Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 6, 2026, 1:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound B Mode Imaging and Elastography

NCT04607187
View directory record Official record
Conditions
Dupuytren's Contractures
Interventions
Not listed
Lead sponsor
Theresa Bass-Goldman
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Real World CCH Study in Adult Females With Cellulite

NCT04170296
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite
Interventions
EN3835
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
11
States / cities
Encino, California • San Diego, California • Solana Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

NCT01987986
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (EFP)
Interventions
Collagenase Clostridium Histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Santa Monica, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221597
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Homewood, Alabama • Phoenix, Arizona • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

NCT02249052
View directory record Official record
Conditions
Lipoma
Interventions
AA4500, placebo
Drug
Lead sponsor
Gerut, Zachary, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Hewlett, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional

Santyl Applications to Diabetic Foot Ulcers

NCT02111291
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions
Collagenase SANTYL® Ointment, Hydrogel (if needed) and foam dressing
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Mesa, Arizona • Carlsbad, California • Castro Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

NCT01613313
View directory record Official record
Conditions
Lipoma
Interventions
Collagenase Clostridium Histolyticum
Drug
Lead sponsor
Zachary Gerut
Individual
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hewlett, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

NCT05419505
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Antifibrinolytic Agent
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture

NCT00528931
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of EN3835 in Participants With Frozen Shoulder

NCT04496167
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
EN3835, Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.

NCT05026216
View directory record Official record
Conditions
Cellulite
Interventions
Qwo
Drug
Lead sponsor
DMR Research, PLLC
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Clostridium Histolyticum Collagenase Injection for Urethral Disease

NCT02948842
View directory record Official record
Conditions
Urethral Stricture
Interventions
Clostridium Histolyticum Collagenase, Saline
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Use of Santyl in Diabetic Foot Ulcers

NCT02581488
View directory record Official record
Conditions
Diabetic Foot, Foot Ulcer, Diabetic
Interventions
Santyl, Product containing silver
Biological · Other
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Sylmar, California • Melbourne, Florida • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221623
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 6, 2026, 1:03 PM EDT